Subtopic Deep Dive
ANCA-Associated Vasculitis
Research Guide
What is ANCA-Associated Vasculitis?
ANCA-associated vasculitis (AAV) comprises granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA), autoimmune small-vessel vasculitides driven by anti-neutrophil cytoplasmic antibodies (ANCA) causing multi-organ inflammation.
AAV affects kidneys, lungs, and other organs, with rituximab emerging as a key therapy over cyclophosphamide for remission induction and maintenance (Stone et al., 2010; 2665 citations; Guillevin et al., 2014; 1049 citations). Genetic distinctions exist between GPA and MPA subsets linked to ANCA specificity (Lyons et al., 2012; 997 citations). EULAR guidelines provide management recommendations (Yates et al., 2016; 1163 citations). Over 10 major trials shape current standards.
Why It Matters
Rituximab reduced relapses compared to cyclophosphamide in severe AAV (Stone et al., 2010; 2665 citations) and outperformed azathioprine for maintenance (Guillevin et al., 2014; 1049 citations), guiding steroid-sparing regimens that lower infection risks. Avacopan inhibits C5a receptors to replace glucocorticoids, improving remission without toxicity (Jayne et al., 2021; 874 citations). Mepolizumab targets eosinophils in EGPA, enabling glucocorticoid reduction (Wechsler et al., 2017; 982 citations). These advances impact treatment for 10-20 per million annually affected patients worldwide.
Key Research Challenges
Relapse Prediction Biomarkers
Persistent ANCA positivity predicts relapses, but lacks specificity for timing interventions (Stone et al., 2010). Trials show variable rituximab durability beyond 18 months (Guillevin et al., 2014). Developing reliable biomarkers remains critical for personalized maintenance.
Genetic Subtype Heterogeneity
Distinct HLA associations differentiate GPA from MPA, influencing PR3- vs MPO-ANCA responses (Lyons et al., 2012; 997 citations). This heterogeneity complicates trial designs and targeted therapies. Integrating genetics into classification criteria is ongoing.
Glucocorticoid Toxicity Reduction
High-dose steroids cause infections and diabetes despite rituximab efficacy (Jones et al., 2010; 1704 citations). Avacopan shows promise but requires long-term safety data (Jayne et al., 2021). Balancing efficacy with steroid minimization drives new trials.
Essential Papers
Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis
John H. Stone, Peter A. Merkel, Robert Spiera et al. · 2010 · New England Journal of Medicine · 2.7K citations
Rituximab therapy was not inferior to daily cyclophosphamide treatment for induction of remission in severe ANCA-associated vasculitis and may be superior in relapsing disease. (Funded by the Natio...
Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis
Rachel Jones, Jan Willem Cohen Tervaert, Thomas Häuser et al. · 2010 · New England Journal of Medicine · 1.7K citations
A rituximab-based regimen was not superior to standard intravenous cyclophosphamide for severe ANCA-associated vasculitis. Sustained-remission rates were high in both groups, and the rituximab-base...
EULAR/PRINTO/PRES criteria for Henoch–Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteria
Seza Özen, Angela Pistorio, S. M. Iusan et al. · 2010 · Annals of the Rheumatic Diseases · 1.4K citations
Netting Neutrophils Induce Endothelial Damage, Infiltrate Tissues, and Expose Immunostimulatory Molecules in Systemic Lupus Erythematosus
Eneida C. Villanueva, Srilakshmi Yalavarthi, Céline C. Berthier et al. · 2011 · The Journal of Immunology · 1.2K citations
Abstract An abnormal neutrophil subset has been identified in the PBMC fractions from lupus patients. We have proposed that these low-density granulocytes (LDGs) play an important role in lupus pat...
EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis
Max Yates, Richard A. Watts, Ingeborg M. Bajema et al. · 2016 · Annals of the Rheumatic Diseases · 1.2K citations
Rituximab versus Azathioprine for Maintenance in ANCA-Associated Vasculitis
Loı̈c Guillevin, Christian Pagnoux, Alexandre Karras et al. · 2014 · New England Journal of Medicine · 1.0K citations
More patients with ANCA-associated vasculitides had sustained remission at month 28 with rituximab than with azathioprine. (Funded by the French Ministry of Health; MAINRITSAN ClinicalTrials.gov nu...
Genetically Distinct Subsets within ANCA-Associated Vasculitis
Paul Lyons, Tim F. Rayner, Sapna Trivedi et al. · 2012 · New England Journal of Medicine · 997 citations
This study confirms that the pathogenesis of ANCA-associated vasculitis has a genetic component, shows genetic distinctions between granulomatosis with polyangiitis and microscopic polyangiitis tha...
Reading Guide
Foundational Papers
Start with Stone et al. (2010; 2665 citations) for rituximab induction evidence, Jones et al. (2010; 1704 citations) for renal focus, and Guillevin et al. (2014; 1049 citations) for maintenance, as they establish core RCT benchmarks cited >5000 times combined.
Recent Advances
Study Jayne et al. (2021; 874 citations) for avacopan steroid-sparing, Wechsler et al. (2017; 982 citations) for EGPA mepolizumab, and Yates et al. (2016; 1163 citations) for updated EULAR management.
Core Methods
Randomized controlled trials dominate (RAVE, RITUXVAS, MAINRITSAN); genetic association studies use HLA imputation (Lyons 2012); NETosis assays assess pathogenesis (Villanueva 2011); EULAR recommendations synthesize evidence grades.
How PapersFlow Helps You Research ANCA-Associated Vasculitis
Discover & Search
Research Agent uses searchPapers and citationGraph on 'rituximab ANCA vasculitis' to map 2665-citation Stone et al. (2010) as central hub, revealing downstream trials like Guillevin et al. (2014); exaSearch uncovers avacopan extensions from Jayne et al. (2021); findSimilarPapers links genetic studies to Lyons et al. (2012).
Analyze & Verify
Analysis Agent applies readPaperContent to extract remission rates from Stone et al. (2010), verifies rituximab superiority via verifyResponse (CoVe) against Jones et al. (2010), and runs PythonAnalysis on trial data for GRADE grading of high-quality RCTs; statistical verification confirms hazard ratios for relapses.
Synthesize & Write
Synthesis Agent detects gaps in relapse biomarkers post-rituximab via gap detection, flags neutrophil NETosis contradictions from Villanueva et al. (2011); Writing Agent uses latexEditText, latexSyncCitations for trial comparison tables, and latexCompile for review manuscripts with exportMermaid timelines of therapy evolution.
Use Cases
"Extract survival curves from RAVE and RITUXVAS trials for meta-analysis"
Analysis Agent → readPaperContent (Stone 2010, Jones 2010) → runPythonAnalysis (pandas survival plots, Kaplan-Meier stats) → GRADE B evidence output with CSV export.
"Draft EULAR guideline update on avacopan integration"
Synthesis Agent → gap detection (Yates 2016 vs Jayne 2021) → Writing Agent → latexEditText (guideline template) → latexSyncCitations → latexCompile (PDF with figures).
"Find code for ANCA genetic risk models"
Research Agent → paperExtractUrls (Lyons 2012) → paperFindGithubRepo → githubRepoInspect → runPythonAnalysis (reproduce HLA associations).
Automated Workflows
Deep Research workflow synthesizes 50+ AAV papers into structured reports: searchPapers → citationGraph → DeepScan checkpoints verify remission data across Stone (2010), Guillevin (2014). Theorizer generates hypotheses on avacopan-NETosis links from Jayne (2021), Villanueva (2011). DeepScan applies 7-step CoVe to guideline adherence in Yates (2016).
Frequently Asked Questions
What defines ANCA-associated vasculitis?
AAV includes GPA, MPA, and EGPA, characterized by ANCA targeting neutrophils, causing pauci-immune small-vessel necrotizing inflammation in kidneys and lungs.
What are key therapeutic methods?
Rituximab induces remission equivalently to cyclophosphamide (Stone et al., 2010; Jones et al., 2010) and maintains it better than azathioprine (Guillevin et al., 2014); avacopan and mepolizumab reduce glucocorticoids (Jayne et al., 2021; Wechsler et al., 2017).
What are seminal papers?
Stone et al. (2010; 2665 citations) established rituximab for induction; Guillevin et al. (2014; 1049 citations) for maintenance; Lyons et al. (2012; 997 citations) defined genetic subsets.
What open problems persist?
Biomarker-validated relapse prevention, steroid-free regimens beyond avacopan, and EGPA-targeted therapies lack long-term data; genetic personalization of rituximab dosing remains unresolved.
Research Vasculitis and related conditions with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching ANCA-Associated Vasculitis with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Vasculitis and related conditions Research Guide